Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2005;112:3617-3623
Published online before print November 28, 2005, doi: 10.1161/CIRCULATIONAHA.105.556274
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
112/23/3617    most recent
CIRCULATIONAHA.105.556274v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, L.
Right arrow Articles by Wang, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, L.
Right arrow Articles by Wang, D. H.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CAPSAICIN
Related Collections
Right arrow Acute myocardial infarction
Right arrow Coronary circulation
Right arrow Genetically altered mice
Right arrowRelated Article

(Circulation. 2005;112:3617-3623.)
© 2005 American Heart Association, Inc.


Heart Failure

TRPV1 Gene Knockout Impairs Postischemic Recovery in Isolated Perfused Heart in Mice

Lihong Wang, MD, PhD*; Donna H. Wang, MD*

From the Department of Medicine, Michigan State University, East Lansing (D.H.W.), and Department of Cardiovascular Sciences, First Affiliated Hospital, College of Medicine, Zhejiang University, China (L.W.).

Correspondence to Donna H. Wang, MD, Department of Medicine, B316 Clinical Center, Michigan State University, East Lansing, MI 48824. E-mail donna.wang{at}ht.msu.edu

Received April 15, 2005; revision received July 22, 2005; accepted August 8, 2005.

Background— Although pharmacological studies suggest that the transient receptor potential vanilloid type 1 (TRPV1) channels expressed in sensory nerve fibers innervating the heart may exert a cardioprotective effect, definitive evidence supporting such a notion is lacking. In addition, function and regulation of sensory neuropeptides, namely, calcitonin gene–related peptide (CGRP) and substance P (SP), in the face of challenges induced by cardiac injury in the presence or absence of the TRPV1 are largely unknown.

Methods and Results— The hearts of gene-targeted TRPV1-null mutant (TRPV1–/–) mice or wild-type (WT) mice were perfused in a Langendorff apparatus in the presence or absence of capsazepine (a TRPV1 receptor antagonist), CGRP, CGRP8–37 (a CGRP receptor antagonist), SP, or RP67580 (a neurokinin-1 [NK1] receptor antagonist) when hearts were subjected to 40 minutes of ischemia and 30 minutes of reperfusion. Hemodynamic alterations and SP release measured by radioimmunoassay were assessed before and after ischemia/reperfusion injury of the heart. Expression of the NK1 receptor in the hearts of TRPV1–/– and WT mice were determined with the use of Western blot analyses. Impairment of postischemic recovery, defined by increased left ventricular end-diastolic pressure (LVEDP) and decreased left ventricular developed pressure (LVDP) and coronary flow (CF), was more severe in TRPV1–/– hearts than in WT hearts. Although it had no effect on postischemic recovery of TRPV1–/– hearts, blockade of the TRPV1 with capsazepine caused a most severe impairment of postischemic recovery in WT hearts compared with untreated WT and TRPV1–/– hearts. Exogenous CGRP and SP produced a significant improvement in postischemic recovery in both TRPV1–/– and WT hearts, and the maximal functional improvement in TRPV1–/– hearts was not different from that of WT hearts except that SP-induced increases in LVDP were larger in the former than in the latter. Blockade of the NK1 receptor with RP67580, but not blockade of the CGRP receptor with CGRP8–37, caused more severe impairment in postischemic recovery in both TRPV1–/– and WT hearts than in untreated hearts in both genotypes. The release of SP after ischemia/reperfusion injury was increased in both WT and TRPV1–/– hearts, albeit with a smaller magnitude of the increase in the latter. Capsazepine attenuated injury-induced SP release in WT but not TRPV1–/– hearts. There was no difference in the expression of the NK1 receptor between the 2 genotype hearts.

Conclusions— Thus, our data show that (1) TRPV1 gene deletion decreases injury-induced SP release and impairs cardiac recovery function after ischemia/reperfusion injury; (2) TRPV1 gene deletion leads to reconditioning of the heart with improved postischemic recovery compared with that induced by acute TRPV1 blockade and in terms of cardiac response to exogenous SP; and (3) blockade of the NK1 but not CGRP receptors worsens postischemic recovery of hearts in both genotypes. Taken together, these data indicate that TRPV1 plays a role in protecting the heart from injury possibly via increasing SP release and that deletion of this receptor reconditions the heart for escaping, at least in part, from injury possibly via enhancing NK1 receptor function.


 

CLINICAL PERSPECTIVE


Related Article:

No Pain, No Gain: The Useful Function of Angina
Roberto Bolli and Ahmed Abdel-Latif
Circulation 2005 112: 3541-3543. [Full Text]



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
T. Kark, Z. Bagi, E. Lizanecz, E. T. Pasztor, N. Erdei, A. Czikora, Z. Papp, I. Edes, R. Porszasz, and A. Toth
Tissue-Specific Regulation of Microvascular Diameter: Opposite Functional Roles of Neuronal and Smooth Muscle Located Vanilloid Receptor-1
Mol. Pharmacol., May 1, 2008; 73(5): 1405 - 1412.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Starr, R. Graepel, J. Keeble, S. Schmidhuber, N. Clark, A. Grant, A. M. Shah, and S. D. Brain
A reactive oxygen species-mediated component in neurogenic vasodilatation
Cardiovasc Res, April 1, 2008; 78(1): 139 - 147.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. Huang, A. Karve, I. Shah, M. C. Bowers, D. J. DiPette, S. C. Supowit, and G. S. Abela
Deletion of the mouse {alpha}-calcitonin gene-related peptide gene increases the vulnerability of the heart to ischemia-reperfusion injury
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1291 - H1297.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
M. Avkiran, A. J. Rowland, F. Cuello, and R. S. Haworth
Protein Kinase D in the Cardiovascular System: Emerging Roles in Health and Disease
Circ. Res., February 1, 2008; 102(2): 157 - 163.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
A. Sexton, M. McDonald, C. Cayla, C. Thiemermann, and A. Ahluwalia
12-Lipoxygenase-derived eicosanoids protect against myocardial ischemia/reperfusion injury via activation of neuronal TRPV1
FASEB J, September 1, 2007; 21(11): 2695 - 2703.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
B. Zhong and D. H. Wang
TRPV1 gene knockout impairs preconditioning protection against myocardial injury in isolated perfused hearts in mice
Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1791 - H1798.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Ieda, H. Kanazawa, Y. Ieda, K. Kimura, K. Matsumura, Y. Tomita, T. Yagi, T. Onizuka, K. Shimoji, S. Ogawa, et al.
Nerve Growth Factor Is Critical for Cardiac Sensory Innervation and Rescues Neuropathy in Diabetic Hearts
Circulation, November 28, 2006; 114(22): 2351 - 2363.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R. Bolli and A. Abdel-Latif
No Pain, No Gain: The Useful Function of Angina
Circulation, December 6, 2005; 112(23): 3541 - 3543.
[Full Text] [PDF]